A calm evidence note
Does a GLP-1 Make You Tired? What the FDA Labels Say
Semaglutide and tirzepatide fatigue rates read straight from the FDA labels: which products tabulate it, which don't, and what the placebo columns show.
On this page
Our clearest pick
CoreAge Rx
From $93/mo
NAD+ nasal spray or injection advertised from $93/month, with online clinical review.
Check availability- Form
- Nasal spray + injection
- Pricing
- Varies by plan
- Review
- Clinician-reviewed intake
- Pharmacy
- Not named
Advertising disclosure · we may earn a commission if you start through this link, at no extra cost to you. This is a note on provider value, not a promise about focus, and what we write about the product is the same either way.
Also compared
HealthRX
From $134/mo
Publishes its whole price ladder in the open — both routes, with the provider visit, the supplies and the shipping already inside the figure.
See all 61 providers comparedFatigue appears in the U.S. prescribing information for several GLP-1 and GIP/GLP-1 products. Some labels report fatigue on its own, while others group it with weakness or other symptoms. The figures below come from specific studies and formulations.
The FDA label table, side by side
Straight from the prescribing information
| Product | In the tabulated adverse-reaction table? | Drug vs placebo |
|---|---|---|
| Wegovy 2.4 mg (semaglutide, obesity) | Yes — Table 3, composite of fatigue and asthenia | 11% vs 5% (N=2,116 vs 1,261) |
| Zepbound (tirzepatide, obesity and OSA) | Yes — weight-reduction trials, composite of asthenia, fatigue, lethargy and malaise | 5% / 6% / 7% at 5, 10, 15 mg vs 3% |
| Saxenda (liraglutide 3 mg, obesity) | Yes — Table 2, adults, fatigue and asthenia as separate rows | Fatigue 7.5% vs 4.6%; asthenia 2.1% vs 0.8% (N=3,384 vs 1,941) |
| Ozempic (semaglutide, type 2 diabetes) | No — narrative text only, above a 0.4% reporting threshold | Not stated; no placebo comparator in the label |
| Mounjaro (tirzepatide, type 2 diabetes) | Narrative reporting in the cardiovascular outcomes trial | 10% of 6,647 adults exposed; no comparator stated for fatigue |
Read that table for thirty seconds and the picture changes from the one you get on a med-spa blog. Three of the five products tabulate fatigue with a placebo comparator. The Ozempic and Mounjaro labels also report fatigue in narrative text.
Wegovy (semaglutide 2.4 mg) lists it in Table 3 of its label as a composite — footnote b of that table states it "includes fatigue and asthenia" — at 11% on drug versus 5% on placebo across 2,116 treated adults and 1,261 placebo1. That is a six-percentage-point difference in this trial pool. These figures apply to the injection, and the label reports tablet safety separately.
Zepbound (tirzepatide) lists it in Table 1 as a broader composite — footnote e: "includes asthenia, fatigue, lethargy, malaise" — and reports it by dose: 5% at 5 mg, 6% at 10 mg, and 7% at 15 mg, against 3% on placebo2. This table is from the weight-reduction trials.
Saxenda (liraglutide 3 mg) is the only one of the five that does not use a composite. Its adult table breaks the two terms out separately: fatigue 7.5% versus 4.6%, and asthenia 2.1% versus 0.8%3. That is a useful accident of drafting, because it shows how much of a composite number is ordinary tiredness versus the more specific complaint of weakness.
Ozempic (semaglutide, for type 2 diabetes) does not tabulate fatigue anywhere. It appears only in a short narrative paragraph headed "Fatigue, Dysgeusia and Dizziness," which says other adverse reactions with a frequency of greater than 0.4% associated with Ozempic include fatigue, dysgeusia and dizziness4. There is no percentage, no denominator, and — critically — no placebo comparator. "Greater than 0.4%" is a reporting threshold, not a rate.
Mounjaro (tirzepatide, for type 2 diabetes) now reports fatigue in 10% of 6,647 adults exposed to the drug in a cardiovascular outcomes trial in people with type 2 diabetes and established cardiovascular disease. The label gives this figure in the narrative and does not give a fatigue comparator alongside it5.
Three traps in reading these numbers
The reason coverage of this topic is so unreliable is that the labels are easy to misread in three specific ways. If you take nothing else from this page, take these.
Trap 1: comparing the Zepbound and Mounjaro percentages directly. Zepbound's 5–7% rates use a composite in weight-reduction trials. The Mounjaro 10% figure refers to fatigue in a cardiovascular outcomes trial with a different population and no comparator listed for this event25.
Trap 2: Wegovy has two different fatigue numbers, and you must name the table. Fatigue is 11% in Table 3, which pools the 2.4 mg trials against placebo1. But the same label's Table 4 — a separate, later trial pool comparing placebo, 2.4 mg and 7.2 mg — reports fatigue at 5% on placebo, 9% on 2.4 mg, and 11% on 7.2 mg1. Same drug, same dose, same label, two different percentages, because they are different trial populations. Neither is wrong. A citation that says "Wegovy fatigue is 11%" without naming the table is not wrong either, but it is not reproducible, and if someone quotes 9% at you they are also reading the label correctly.
Trap 3: with Saxenda, the usual adult-versus-pediatric tell does not fire. Many drug labels contain an adult adverse-reaction table and a separate adolescent one, and writers grab the wrong table constantly. The usual giveaway is a 0% placebo rate, which almost never happens in a large adult trial. Saxenda breaks that heuristic: its adult table (Table 2) and its pediatric table (Table 3) both report non-zero placebo fatigue — 4.6% in adults and 3.2% in the 12-to-under-18 trial3. So you cannot spot the error by looking at the placebo column. You have to check the denominators: N=1,941 placebo and N=3,384 Saxenda is the adult table; N=126 and N=125 is the pediatric one. The figures on this page are the adult rows.
And one corollary worth stating plainly: anyone publishing a specific Ozempic fatigue percentage is not getting it from FDA labeling. They may be quoting a trial publication, a different product's table, or nothing at all — but the number is not in the label, because the label does not contain one.
So does semaglutide make you tired? Does tirzepatide?
On the labeled evidence: semaglutide at the obesity dose, yes, in about 11% of people versus 5% on placebo — a genuine but minority effect1. Tirzepatide at obesity doses, yes, in 5–7% versus 3%, rising with dose2. Liraglutide at the obesity dose, yes, 7.5% versus 4.6%3. The Ozempic injection label gives a reporting threshold, and the Mounjaro label gives a rate for one cardiovascular outcomes trial45.
Notice how modest those gaps are. Subtract the placebo column and the drug-attributable excess is roughly 6 percentage points for Wegovy, 2–4 for Zepbound, and 3 for Saxenda. These are differences between groups. They do not tell you why a particular person feels tired.
What is driving your fatigue
- Direct labeled drug effect (obesity doses)Moderate evidence
Tabulated with a placebo comparator for Wegovy, Zepbound and Saxenda; drug-attributable excess is roughly 2 to 6 percentage points.
- Direct drug effect (diabetes formulations)No evidence
Ozempic injection gives a threshold. Mounjaro reports 10% in its cardiovascular outcomes trial without listing a fatigue comparator.
- Eating far below your energy needsModerate evidence
Reduced appetite and intake can contribute to tiredness.
- Mild dehydration from reduced intake and GI side effectsModerate evidence
A 1-2% body-weight fluid deficit measurably worsens fatigue and attention, in experimental studies.
- Low or unstable blood sugarModerate evidence
Well documented as a cause of tiredness and slowed thinking; risk rises sharply alongside insulin or a sulfonylurea.
- A supplement will restore your energy on a GLP-1No evidence
No product has been shown to do this. Check intake, fluids, glucose and sleep first.
What is actually making you tired
This is where the label stops helping and mechanism starts. The labels count reported fatigue without identifying its mechanism. Reduced food or fluid intake, low blood sugar and poor sleep are worth considering. Research on mood or cognition measures different outcomes from physical fatigue6.
You are eating far less than you think. Appetite suppression is the point of the drug, and a great many people end up well below their energy needs without registering it, particularly in the first weeks after a dose increase. Bring any marked change in food intake or strength to your prescriber.
You are mildly dehydrated. Nausea, vomiting, diarrhea and simply not feeling like drinking add up fast. A fluid deficit of only 1–2% of body weight measurably worsens fatigue, mood and attention, in controlled research7. It is the most fixable item on this list, and we cover the threshold and the correction in dehydration and brain fog.
Your blood sugar is low or unstable. GLP-1s rarely cause outright hypoglycaemia on their own in people without diabetes, but combined with very low intake, skipped meals, or insulin or a sulfonylurea, low glucose is a direct and well-documented cause of tiredness and slowed thinking8. If your fatigue comes with shakiness or sweating and lifts after you eat, that is the pattern — and it is a prescriber conversation, especially on combination therapy. The wider picture is in blood sugar and brain fog.
You are not sleeping as well as you assume. Reflux, nocturnal nausea and interrupted sleep are common early on, and short or fragmented sleep independently degrades attention, working memory and processing speed9. If the tiredness is worst on waking and improves through the morning, read why you wake up foggy before you blame the injection. Untreated sleep apnoea is its own major contributor here — and one of these drugs is now actually approved to treat it, which we cover in Zepbound for sleep apnea.
When it usually starts, and when to call someone
The labeled fatigue is concentrated early. Saxenda's label is explicit about this: events of asthenia, fatigue, malaise, dysgeusia and dizziness "were mainly reported within the first 12 weeks of treatment" and were often co-reported alongside gastrointestinal events like nausea and vomiting3. That co-reporting is the most informative sentence in any of the five labels, because it points at the same causal chain described above — feeling sick, eating and drinking less, feeling wiped out — rather than at a direct sedating effect.
The timing reported for Saxenda does not establish how long fatigue lasts with other drugs or after a dose increase. Fatigue that is severe, that does not improve between escalations, or that comes with dizziness on standing, a racing heart, or new neurological symptoms is worth a call to your prescriber rather than a supplement. And nothing here is a reason to change your own dose.
The bottom line
Fatigue is reported in these labels, with different study populations and reporting methods. Wegovy 2.4 mg: 11% versus 5% in Table 3, 9% versus 5% in Table 4 — name the table1. Zepbound: 5%, 6%, 7% by dose versus 3%, as a composite that includes asthenia, lethargy and malaise2. Saxenda in adults: fatigue 7.5% versus 4.6%, asthenia 2.1% versus 0.8%, with the adult table identifiable by its N of 1,941 and 3,3843. Ozempic: a narrative mention above a 0.4% reporting threshold with no comparator4. Mounjaro: fatigue was reported in 10% of adults exposed in the cardiovascular outcomes trial, with no event comparator listed5. If tiredness persists, discuss your symptoms and medication with your prescriber. If what you are noticing is mental haze rather than physical tiredness, that is a different question, and we take it apart in brain fog on Ozempic and other GLP-1s and in what the GLP-1 cognition trials actually measured.
A few gentle questions
Does semaglutide make you tired?
At the obesity dose, yes, for a minority of people. Wegovy 2.4 mg lists fatigue in Table 3 of its FDA label as a composite of fatigue and asthenia at 11% versus 5% on placebo. In a separate trial pool in Table 4 of the same label, the 2.4 mg rate is 9% versus 5%. Ozempic — the same molecule at diabetes doses — does not tabulate fatigue at all; it appears only in a narrative paragraph noting a frequency above 0.4%, with no placebo comparator.
Does tirzepatide make you tired?
The obesity label says yes, at 5% on 5 mg, 6% on 10 mg and 7% on 15 mg, against 3% on placebo — reported as a composite that includes asthenia, fatigue, lethargy and malaise. That dose gradient is what you would expect from a real drug contribution. The Mounjaro label reports fatigue in 10% of adults exposed in one cardiovascular outcomes trial in people with type 2 diabetes and established cardiovascular disease. The label does not list a comparator for fatigue in that trial.
What percentage of people get fatigue on Ozempic?
The FDA label does not say. Fatigue appears only in a narrative paragraph stating that other adverse reactions with a frequency greater than 0.4% associated with Ozempic include fatigue, dysgeusia and dizziness. There is no percentage, no denominator and no placebo column. Anyone publishing a specific Ozempic fatigue percentage is not taking it from FDA labeling.
Why do I feel so tired on a GLP-1?
Possible contributors include eating well below your energy needs without realizing it, mild dehydration from reduced drinking plus nausea or diarrhea, low or unstable blood sugar, and disrupted sleep. Each independently causes tiredness and slowed thinking. The labels support this reading: Saxenda's notes that fatigue, asthenia and malaise were mainly reported in the first 12 weeks and were often co-reported with gastrointestinal events.
How long does GLP-1 fatigue last?
Saxenda’s label says fatigue and several related events were mainly reported in the first 12 weeks. That does not establish the duration of symptoms for a given person or other medications. Fatigue that is severe, that does not improve between escalations, or that comes with dizziness on standing, a racing heart or new neurological symptoms is a reason to contact your prescriber rather than push through — and never adjust your own dose.
Is fatigue worse on Wegovy or Zepbound?
On the labeled numbers Wegovy shows the larger gap over placebo (11% vs 5%, roughly six percentage points) than Zepbound (5-7% vs 3%, roughly two to four). But the two are not measured the same way — Zepbound's figure is a broader composite including lethargy and malaise, and the trials, populations and placebo rates differ. The labels support saying each drug lists fatigue; they do not support a head-to-head ranking.
Where this comes from
- Novo Nordisk Inc. (2026). WEGOVY (semaglutide) injection and tablet — full prescribing information. DailyMed, U.S. National Library of Medicine (setid ee06186f-2aa3-4990-a760-757579d8f77b). https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
- Eli Lilly and Company (2026). ZEPBOUND (tirzepatide) injection — full prescribing information. DailyMed, U.S. National Library of Medicine (setid 487cd7e7-434c-4925-99fa-aa80b1cc776b). https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
- Novo Nordisk Inc. (2026). SAXENDA (liraglutide) injection — full prescribing information. DailyMed, U.S. National Library of Medicine (setid 3946d389-0926-4f77-a708-0acb8153b143). https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143
- Novo Nordisk Inc. (2026). OZEMPIC (semaglutide) injection — full prescribing information. DailyMed, U.S. National Library of Medicine (setid adec4fd2-6858-4c99-91d4-531f5f2a2d79). https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79
- Eli Lilly and Company (2026). MOUNJARO (tirzepatide) injection — full prescribing information. DailyMed, U.S. National Library of Medicine (setid d2d7da5d-ad07-4228-955f-cf7e355c8cc0). https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0
- Choudhury I, Ward JH, Mahesh S, Alam U, et al. (2026). Effect of Glucagon-Like-Peptide-1 Receptor Agonists (GLP-1 RA) on Neuropsychiatric Outcomes: A Systematic Review and Meta-Analysis. Clinical Therapeutics. 2026;48(4):347-384. https://pubmed.ncbi.nlm.nih.gov/41862354/
- Ganio MS, Armstrong LE, Casa DJ, McDermott BP, et al. (2011). Mild dehydration impairs cognitive performance and mood of men. British Journal of Nutrition. 2011;106(10):1535-1543. https://pubmed.ncbi.nlm.nih.gov/21736786/
- Warren RE, Frier BM (2005). Hypoglycaemia and cognitive function. Diabetes, Obesity & Metabolism. 2005;7(5):493-503. https://pubmed.ncbi.nlm.nih.gov/16050942/
- Khan MA, Al-Jahdali H (2023). The consequences of sleep deprivation on cognitive performance. Neurosciences (Riyadh). 2023;28(2):91-99. https://pubmed.ncbi.nlm.nih.gov/37045455/
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.
Read on, gently
NAD+ for Cognitive Energy & Fatigue: What the Evidence Shows
NAD+ precursors reliably raise the biomarker but haven't beaten placebo for fatigue or mental energy in the best trials. An honest, evidence-first review.
ReadSemaglutide & Brain Fog: What the Cognition Trials Found
What semaglutide cognition trials found, why brain-fog symptoms are a separate question, and what the evidence does and does not show.
ReadWhat Is Food Noise? Meaning, Measurement & How to Quiet It
Food noise is persistent, unwanted thinking about food. The formal definition, the questionnaire behind it, the critique, and what GLP-1s do and don't prove.
ReadEnhance MD NAD+ Review: Read the Four-Week Billing First
Enhance MD offers NAD+ injections and wafers. We compare four-week billing, longer plans, support, pharmacy disclosures and the limits of the evidence.
ReadPOTS Brain Fog: Why Posture Matters, and What Studies Show
Brain fog can accompany POTS while standing or seated. Learn what small cognitive studies found and how to describe symptoms for clinical evaluation.
ReadNAD+ Injection Side Effects: Safety Questions Before Treatment
FDA reports, sterile-compounding risks, and limits of NAD+ injection evidence. What to ask a prescriber and how to respond to concerning symptoms.
Read